Spacelabs Medical
This article was originally published in The Gray Sheet
Executive Summary
Patient monitoring firm expects $30-50 mil. in incremental revenues over the next five years as a result of CMS' Oct. 17 favorable reimbursement decision for ambulatory blood pressure monitoring (ABPM) for the diagnosis of suspected white coat hypertension, according to an Oct. 25 announcement. Separately, the firm reports third-quarter (ended Sept. 29) revenue of $57 mil., down from $65.2 mil. in the comparable period in 2000, due in part to "the global economic and political environment"
You may also be interested in...
Spacelabs Medical
Coverage, billing and claims processing instructions for ambulatory blood pressure monitoring (ABPM) for Medicare beneficiaries with suspected "white coat" hypertension recently issued to intermediaries by CMS will be effective April 1, the patient monitoring firm announces Jan. 7. Applicable health care common procedure coding system (HCPCS) codes have already been established, according to Spacelabs. CMS issued a favorable coverage decision for the treatment Oct. 17. As a result of coverage, Spacelabs anticipates $30-50 mil. in incremental revenues for its Ultralite ABPM monitor over the next five years (1"The Gray Sheet" Oct. 29, 2001, p. 23). Pricing will be set by local Medicare contractors until CMS issues a national payment amount under the physician fee schedule...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.